Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Interest Expenses (2016 - 2024)

Historic Interest Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q4 2024 value amounting to $4.6 million.

  • Lifecore Biomedical, Inc. \De\'s Interest Expenses rose 4264.12% to $4.6 million in Q4 2024 from the same period last year, while for May 2025 it was $9.0 million, marking a year-over-year decrease of 3846.0%. This contributed to the annual value of $14.7 million for FY2024, which is 1489.93% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Interest Expenses amounted to $4.6 million in Q4 2024, which was up 4264.12% from $4.4 million recorded in Q3 2024.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Interest Expenses ranged from a high of $6.1 million in Q3 2021 and a low of -$1.8 million during Q2 2020
  • Moreover, its 5-year median value for Interest Expenses was $3.2 million (2022), whereas its average is $3.2 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Interest Expenses plummeted by 19253.2% in 2020, and later soared by 27191.82% in 2021.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Interest Expenses stood at $1.6 million in 2020, then soared by 73.37% to $2.8 million in 2021, then surged by 30.39% to $3.6 million in 2022, then dropped by 10.17% to $3.2 million in 2023, then soared by 42.64% to $4.6 million in 2024.
  • Its Interest Expenses stands at $4.6 million for Q4 2024, versus $4.4 million for Q3 2024 and $4.9 million for Q2 2024.